TABLE 9.

Seroprotection rates per time point and study for the anti-HBs in-house assay versus the AUSAB RIA and EIA reference assays

StudyNo. of subjects/groupaTime pointb% Seroprotection in:
Vaccine group 1Vaccine group 2Vaccine group 3
In-house assayRIAEIAIn-house assayRIAEIAIn-house assayEIA
A72PI, mo 115.320.80.02.7
72PII, mo 280.681.923.626.4
72PII, mo 695.893.159.756.9
72PIII, mo 798.698.681.983.3
B51PI, mo 147.149.063.663.6
51PII, mo 260.860.881.881.8
50PII, mo 648.042.085.281.5
47PIII, mo 772.372.396.296.2
C100PI, mo 12.02.09.712.5
72PII, mo 280.668.168.169.4
72PII, mo 693.193.195.895.8
72PIII, mo 798.697.2100.0100.0
D72PIII, mo 797.295.897.297.297.297.2
E134PI/II, mo 253.040.341.890.486.886.8
145PII/III, mo 799.398.699.3100.0100.0100.0
F50Pre13.816.912.212.2
50PII, mo 698.098.096.096.0
50PII, mo 894.094.0100.0100.0
50PIII, mo 9100.0100.0100.0100.0
G34Pre, mo 1.552.949.059.668.4
47PIII, mo 7100.0100.095.995.0
53PIII, mo 1596.696.693.096.0
57PIV, mo 6100.0100.098.398.3
  • a If the number between the two groups was different, the lowest number was taken.

  • b Pre, sample taken prior to vaccination; PI to PIV, postdose months 1 to 4, respectively; mo 1, mo 2, etc., study month 1, study month 2, etc.